Kathryn Stiede

Statistics

Publications

Citations

179

H-Index

Active since

2011

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Dana-Farber Cancer Institute

Kathryn Stiede is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, tyrosine kinase inhibitors, and pharmacology.

Publications per year

2011–2017

Publications

Acetyl‐coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double‐blind, crossover study

Kathryn Stiede, Wenyan Miao, Heather Blanchette et al. · Hepatology · 2017 · 115 citations · Full text

Medicine, Biochemistry, Pharmacology +17

Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).

Jennifer R. Brown, Jeff P. Sharman, Wael A. Harb et al. · Journal of Clinical Oncology · 2012 · 32 citations

Medicine, Hematology, Pharmacology +17

Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies,

Erica Evans, Richland Tester, Sharon Aslanian et al. · Blood · 2011 · 20 citations

Medicine, Medicinal Chemistry, Pharmacology +10

2.23 Covalent Inhibition of Btk with Clinical Development Compound AVL-292 Disrupts Signaling That Maintains the Microenvironment Necessary for Chronic Lymphocytic Leukemia Growth

Erica Evans, Sabine Ponader, Russell Karp et al. · Clinical Lymphoma Myeloma & Leukemia · 2011 · 12 citations

Medicine, Cancer Biology, Oncology +13

1–4 of 4